Eupraxia Pharmaceuticals Inc. Common Stock Cash Flow-to-Debt Ratio
Eupraxia Pharmaceuticals Inc. Common Stock cash flow-to-debt ratio. Eupraxia Pharmaceuticals Inc. Common Stock (EPRX) has a Cash Flow-to-Debt Ratio of -0.83x as of September 2025, meaning its operating cash flow of $-4.51 Million could theoretically repay -1% of its total liabilities ($5.43 Million) in one year. See Eupraxia Pharmaceuticals Inc. Common Sto leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Eupraxia Pharmaceuticals Inc. Common Stock (2017–2024)
Cash flow-to-debt ratio of Eupraxia Pharmaceuticals Inc. Common Stock from 2017 to 2024. Historical debt coverage capacity for Eupraxia Pharmaceuticals Inc. Common Stock across 8 annual periods. Check Eupraxia Pharmaceuticals Inc. Common Sto investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Eupraxia Pharmaceuticals Inc. Common Stock Cash Flow-to-Debt Ratio by Year (2017–2024)
Eupraxia Pharmaceuticals Inc. Common Stock cash flow-to-debt ratio by year from 2017 to 2024. Year-by-year debt coverage analysis for Eupraxia Pharmaceuticals Inc. Common Stock. For the full cash flow conversion analysis, see cash efficiency ratio of Eupraxia Pharmaceuticals Inc. Common Sto.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -9.67x | $-29.99 Million | $3.10 Million | ▼ -802.5% |
| 2023 | -1.07x | $-20.75 Million | $19.37 Million | ▼ -20.0% |
| 2022 | -0.89x | $-14.40 Million | $16.13 Million | ▲ +6.7% |
| 2021 | -0.96x | $-11.58 Million | $12.10 Million | ▼ -5375.2% |
| 2020 | -0.02x | $-403.78K | $23.12 Million | ▲ +92.8% |
| 2019 | -0.24x | $-5.17 Million | $21.42 Million | ▲ +58.4% |
| 2018 | -0.58x | $-8.32 Million | $14.34 Million | ▲ +91.9% |
| 2017 | -7.20x | $-5.30 Million | $735.82K | — |